Safety of Streptococcus pyogenes Vaccines : Anticipating and Overcoming Challenges for Clinical Trials and Post-Marketing Monitoring
© The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America..
Streptococcus pyogenes (Strep A) infections result in a vastly underestimated burden of acute and chronic disease globally. The Strep A Vaccine Global Consortium's (SAVAC's) mission is to accelerate the development of safe, effective, and affordable S. pyogenes vaccines. The safety of vaccine recipients is of paramount importance. A single S. pyogenes vaccine clinical trial conducted in the 1960s raised important safety concerns. A SAVAC Safety Working Group was established to review the safety assessment methodology and results of more recent early-phase clinical trials and to consider future challenges for vaccine safety assessments across all phases of vaccine development. No clinical or biological safety signals were detected in any of these early-phase trials in the modern era. Improvements in vaccine safety assessments need further consideration, particularly for pediatric clinical trials, large-scale efficacy trials, and preparation for post-marketing pharmacovigilance.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:77 |
|---|---|
| Enthalten in: |
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America - 77(2023), 6 vom: 18. Sept., Seite 917-924 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Asturias, Edwin J [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Acute rheumatic fever |
|---|
| Anmerkungen: |
Date Completed 20.09.2023 Date Revised 10.10.2023 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1093/cid/ciad311 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM35734653X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM35734653X | ||
| 003 | DE-627 | ||
| 005 | 20231226072408.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/cid/ciad311 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1191.xml |
| 035 | |a (DE-627)NLM35734653X | ||
| 035 | |a (NLM)37232372 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Asturias, Edwin J |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Safety of Streptococcus pyogenes Vaccines |b Anticipating and Overcoming Challenges for Clinical Trials and Post-Marketing Monitoring |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 20.09.2023 | ||
| 500 | |a Date Revised 10.10.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America. | ||
| 520 | |a Streptococcus pyogenes (Strep A) infections result in a vastly underestimated burden of acute and chronic disease globally. The Strep A Vaccine Global Consortium's (SAVAC's) mission is to accelerate the development of safe, effective, and affordable S. pyogenes vaccines. The safety of vaccine recipients is of paramount importance. A single S. pyogenes vaccine clinical trial conducted in the 1960s raised important safety concerns. A SAVAC Safety Working Group was established to review the safety assessment methodology and results of more recent early-phase clinical trials and to consider future challenges for vaccine safety assessments across all phases of vaccine development. No clinical or biological safety signals were detected in any of these early-phase trials in the modern era. Improvements in vaccine safety assessments need further consideration, particularly for pediatric clinical trials, large-scale efficacy trials, and preparation for post-marketing pharmacovigilance | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Streptococcus pyogenes | |
| 650 | 4 | |a acute rheumatic fever | |
| 650 | 4 | |a clinical trial | |
| 650 | 4 | |a safety | |
| 650 | 4 | |a vaccine | |
| 650 | 7 | |a Streptococcal Vaccines |2 NLM | |
| 700 | 1 | |a Excler, Jean-Louis |e verfasserin |4 aut | |
| 700 | 1 | |a Ackland, James |e verfasserin |4 aut | |
| 700 | 1 | |a Cavaleri, Marco |e verfasserin |4 aut | |
| 700 | 1 | |a Fulurija, Alma |e verfasserin |4 aut | |
| 700 | 1 | |a Long, Raj |e verfasserin |4 aut | |
| 700 | 1 | |a McCulloch, Mignon |e verfasserin |4 aut | |
| 700 | 1 | |a Sriskandan, Shiranee |e verfasserin |4 aut | |
| 700 | 1 | |a Sun, Wellington |e verfasserin |4 aut | |
| 700 | 1 | |a Zühlke, Liesl |e verfasserin |4 aut | |
| 700 | 1 | |a Kim, Jerome H |e verfasserin |4 aut | |
| 700 | 1 | |a Dale, James B |e verfasserin |4 aut | |
| 700 | 1 | |a Steer, Andrew C |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical infectious diseases : an official publication of the Infectious Diseases Society of America |d 1992 |g 77(2023), 6 vom: 18. Sept., Seite 917-924 |w (DE-627)NLM012603007 |x 1537-6591 |7 nnns |
| 773 | 1 | 8 | |g volume:77 |g year:2023 |g number:6 |g day:18 |g month:09 |g pages:917-924 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/cid/ciad311 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 77 |j 2023 |e 6 |b 18 |c 09 |h 917-924 | ||